.jpg "Aerie Pharma (NASDAQ: AERI)")
Yesterday, the CSO of Aerie Pharma (NASDAQ: AERI), Casey Kopczynski, sold shares of AERI for $646.2K.
In addition to Casey Kopczynski, 2 other AERI executives reported Sell trades in the last month.
See today’s analyst top recommended stocks >>
Currently, Aerie Pharma has an average volume of 636.4K. The Company has a Price to Book ratio of 10.5750.
Based on 4 analyst ratings, the analyst consensus is Strong Buy with an average price target of $81.75, reflecting a -22.6% downside.
In the last 30 days, insiders have sold $646.2K worth of AERI shares and purchased $99.69K worth of AERI shares. The insider sentiment on Aerie Pharma has been positive according to 20 insider trades in the past three months. This sentiment is slightly higher than the average sentiment of company insiders in this sector.
Company insider trades’ information is brought to you by the DailyInsider, a proprietary algorithm that analyzes insider trading activity to detect the most attractive trading opportunities. To subscribe to the DailyInsider visit this page.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Aerie Pharmaceuticals, Inc. is a clinical stage pharmaceutical company, which engages in the discovery, development, and commercialization of therapies for the treatment of patients with glaucoma and diseases of the eye. Its products include Rhopressa and Roclatan.
